... itraconazole (SB ITZ) overcomes the limitations of conventional itraconazole (CITZ) such as interindividual variability and reduced bioavailability. It has been approved for systemic mycoses in Australia and Europe as 50 mg and the USA as 65 mg and in India as 50 mg, 65 mg, 100 mg, and 130 mg. However, data...

...J.M. Lachapelle; P. De Doncker; D. Tennstedt; G. Cauwenbergh; P.A.J. Janssen Itraconazole is an orally active triazole antifungal which has been compared to griseofulvin in a number of double-blind trials. In dermatophytosis with a non-fixed treatment regimen for a maximum of 3 months, itraconazole...

..., such as itraconazole, may be particularly useful. The risk/benefit ratio for any such treatment is determined by its tolerability profile and the duration of therapy. Objective: The aim was to compare the efficacy and tolerance of a shorter treatment regimen, using a higher dose of itraconazole, with a standard...

... and oral administration of vitamin E, there was an improvement in the nails. The improvement of the yellow nails was however more discernible subsequent to the introduction of itraconazole pulse therapy for secondary onychomycosis suggesting an effect of this treatment on ungual growth. 7 10 2009...

... microscopic examination. Treatment with oral itraconazole initially resulted in partial improvement but later became ineffective. The rash virtually disappeared with administration of minocycline. These observations indicate that the role of Malassezia yeasts in the pathogenesis of this disease is probably...

...P.R. Hull The treatment of onychomycosis has improved considerably following the introduction of the oral antifungals terbinafine and itraconazole. The pharmacokinetic characteristics of both these drugs has made short treatment times effective. Patients with a culture-proven dermatophyte infection...

.... Exposure of nail fragments to terbinafine (0.25 mg/l for 3 h) inhibited invasion by T. mentagrophytes, C. albicans and the non-dermatophytic moulds. Itraconazole (0.25 mg/l for 3 h) prevented nail plate invasion by T. mentagrophytes, A. versicolor and Fusarium but did not totally inhibit the surface growth...

... patients have been treated worldwide with terbinafine, mostly for 12 weeks for toe-nail onychomycosis. Gastro-intestinal disturbance and minor skin rashes are seen in 5 and 2% of patients, respectively. Antifungal, topical, systemic Dermatophyte Scalp Skin, plantar Comparative trials Itraconazole...

...E.K.A. Van Doorslaer; G. Tormans; A.K. Gupta; K. Van Rossem; A. Eggleston; D.J. Dubois; P. De Doncker; E. Haneke Background : The strategies for the management of onychomycosis have changed since the availability of the newer generation of antifungal agents, particularly, itraconazole...

... antifungal therapy with itraconazole or terbinafine. Multiple-sequential strains from 11 patients were included in the study. Susceptibility testing of these strains was performed against 4 antifungals, itraconazole, ketoconazole, terbinafine and ciclopirox, using the broth microdilution method as per...

.... In contrast, clinical improvement and decreased serum IgE were obtained in patients with positive Malassezia radioallergosorbent tests (RASTs) who were treated by oral ketoconazole. Some preliminary data suggested that oral itraconazole treatment in AD patients reduced the need for topical corticosteroids...

.... Systemic cryptococcosis and immunosuppression was excluded by appropriate tests. Complete healing was achieved after 10 months of itraconazole 100 mg/12 h and surgical excision of the remaining lesion. Our literature review shows another 16 cases of primary cutaneous cryptococcosis in nonimmunocompromised...

...Aditya K. Gupta; Teodora Gregurek-Novak Background:Scopulariopsis brevicaulis is a common non-dermatophyte mould that can cause onychomycosis. Objective: To evaluate the efficacy and safety of the oral antifungal agents griseofulvin, ketoconazole, itraconazole, fluconazole and terbinafine...

... medical history, means that the majority are predictable and can be managed successfully. Drug interactions involving oral antifungal agents such as itraconazole, fluconazole and terbinafine have been studied extensively and are well understood. When problems are known to arise, they can often be overcome...

... antifungal therapy. There is relatively limited data regarding the use of the newer oral antifungal agents, e.g. itraconazole, in the treatment of these mycoses in children. Objective: We wished to determine the efficacy and safety of itraconazole continuous therapy in the management of cutaneous fungal...

...D.L. Wang; A.P. Wang; R.Y. Li; R. Wang Objective: To evaluate the efficacy and safety of a 1-week intermittent itraconazole dosing schedule for onychomycosis. Methods: In this multicenter, open-label study, 646 patients received itraconazole 200 mg twice daily for 1 week/month, followed by 3 weeks...

..., for example with the triazole antifungal itraconazole. Itraconazole can inhibit the metabolism of drugs by CYP 3A4 and therefore might affect the efficacy of antidiabetic agents. Objective: To investigate this, we assessed the safety of itraconazole in diabetic patients with onychomycosis or dermatomycoses...

... Sporotrichin test Itraconazole A 60-year-old Japanese man, working as a farmer, was admitted in September 1996 with a 6-month history of a subcutaneous tumor in the right abdominal wall. A biopsy was subsequently performed, and the tumor was diagnosed as non-Hodgkin’s lymphoma (stage IV, diffuse small...

... suppurating lesions. Terbinafine and itraconazole seem to be promising therapies with shorter treatment durations than griseofulvin. Objective: The objective of the present study was to test the sensitivity of different species of dermatophytes towards terbinafine and itraconazole, and to compare the results...

...E. Svejgaard; C. Avnstorp; B. Wanscher; J. Nilsson; A. Heremans Background: Treatment of plantar or moccasin-type tinea pedis with conventional oral antifungal agents produces poor response rates. Itraconazole is a synthetic, broad-spectrum, orally active antifungal agent with pronounced...